. 2018 Sep 5;26(1):165–180. doi: 10.1530/ERC-18-0134
This work is licensed under a Table 1.
Clinical details – summary table.
| Paired | Unpaired | All | |
|---|---|---|---|
| Samples (n) | 27 | 20 | 47 |
| Patients (n) | 25 | 15 | 40 |
| Sex | |||
| Male; n (%) | 12 (48) | 7 (47) | 19 (47.5) |
| Female; n (%) | 13 (52) | 8 (53) | 21 (52.5) |
| Age (years) | |||
| Mean ± s.e.m. | 46.8 ± 4.0 | 46.2 ± 3.4 | 46.6 ± 2.8 |
| Range | 12–78 | 15–68 | 12–78 |
| Size (mm) | |||
| Mean ± s.e.m. | 49 ± 4 | 47 ± 7 | 48 ± 4 |
| Range | 8–87 | 13–120 | 8–120 |
| Location | |||
| Adrenal (%) | 27 (100) | 7 (35) | 34 (72) |
| PGL (%) | 0 (0) | 13 (65) | 13 (28) |
| Mode of diagnosis | |||
| Symptomatic (%) | 9 (33) | 9 (45) | 18 (38) |
| Incidental (%) | 14 (52) | 7 (35) | 21 (45) |
| Screening (%) | 4 (15) | 4 (20) | 8 (17) |
| Germline mutation (patients) (%) | 5 (25) | 8 (53) | 13 (33.5) |
| SDHA | 0 | 1 | 1 |
| SDHB | 1 | 4 | 5 |
| VHL | 3 | 2 | 5 |
| MEN2 | 1 | 1 | 2 |
| Germline mutation (tumors) (%) | 7 (26) | 13 (65) | 20 (42.6) |
| SDHA | 0 | 3 | 3 |
| SDHB | 1 | 5 | 6 |
| VHL | 5 | 4 | 9 |
| MEN2 | 1 | 1 | 2 |
Incidental, diagnosis due to investigation for another unrelated condition; MEN2, multiple endocrine neoplasia 2; mode of diagnosis – symptomatic, diagnosis due to symptoms or signs of catecholamine excess leading to diagnosis; PGL, paraganglioma; screening, diagnosis during a screening program in individuals with known pheo/PGL predisposition; SDH, succinate dehydrogenase; s.e.m., standard error of the mean; VHL, von Hippel–Lindau.